Relmada Therapeutics, Inc. · NASDAQ:RLMD
Squadron Capital Management LLC reported a 7.00% stake in Relmada Therapeutics, Inc. (Schedule 13G/A)
Event Jun 30, 2026 · Filed Aug 14, 2026
Squadron Capital Management LLC reported a 7.00% stake in Relmada Therapeutics, Inc., 7,350,000 shares, as a passive investor on Jun 30, 2026. Filed Aug 14, 2026 (Schedule 13G/A).
- Stake
- 7.00%
- Shares
- 7,350,000
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 4 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Squadron Master Fund LP | 7.00% | 7,350,000 |
| Squadron Capital Management LLC | 7.00% | 7,350,000 |
| Matthew Sesterhenn | 7.00% | 7,350,000 |
| William Blank | 7.00% | 7,350,000 |
Source
Related
- Relmada Therapeutics, Inc.
- Squadron Capital Management LLC
- Relmada Therapeutics, Inc. shareholders
- Schedule 13G/A · Squadron Capital Management LLC · Feb 17, 2026
- Schedule 13G/A · Squadron Capital Management LLC · Aug 14, 2025
- Schedule 13G · Squadron Capital Management LLC · May 1, 2025
- Form 4 · Shenouda Maged · Sep 11, 2026
- Form 4 · Traversa Sergio · Sep 11, 2026
- Schedule 13G · BlackRock, Inc. · Jul 29, 2026
- Schedule 13G · Millennium Management LLC · Jun 22, 2026
- Schedule 13G · Venrock Healthcare Capital Partners III, L.P. · Jun 9, 2026